Sermorelin
Also called sermorelin acetate, Geref, Geref Diagnostic, GHRH(1-29)-NH2, GRF(1-29)-NH2.
Sermorelin had FDA-approved products that FDA records now list as discontinued. This page cites 1 source, and the strongest evidence comes from human trials.
- Status
- Approved, now discontinued
- Form
- Injection
- Half-life
- Not modeled
- Strongest evidence
- Human trials
- Cited claims
- 1
- Last updated
- November 6, 2026
What the evidence says
Each claim names the kind of study behind it, what it can't tell you, and where it comes from.
Human trials
A randomized Geref trial found increased IGF-1 and lean body mass compared with placebo in men with HIV-associated lipodystrophy.
Limits: The 12-week study enrolled 31 men aged 18 to 60. IGF-1 was the primary outcome. The between-group visceral-fat comparison was not statistically significant. This does not establish longevity benefits or the effectiveness of current compounded products.
Regulatory status
United States
As of November 6, 2026, Geref is a historical FDA-approved product that is discontinued. Its diagnostic and pediatric treatment applications had different indications. FDA withdrew their approvals in 2009 and determined in 2013 that neither product left sale for safety or effectiveness reasons.
United States
Compounded sermorelin products are not FDA-approved. Geref's historical approvals do not approve a current compounded preparation or an adult anti-aging use.